Affaan Shaikh’s new venture aims to replace subjective mental health check-ups with a wearable platform capable of continuous brain monitoring and real-time, personalized interventions.
Entrepreneur and artificial intelligence researcher Affaan Shaikh has officially emerged from stealth mode to launch Neuratia Labs, a neurotechnology startup building non-invasive systems to measure and interpret brain activity in real time. The company’s core mission is to transition neurological and mental health care away from subjective, episodic evaluations and toward continuous, data-driven diagnostics.
Mental and neurological conditions impact a massive segment of the global population, yet standard clinical practice remains heavily tethered to self-reported symptoms and infrequent doctor visits. While the broader healthtech sector has successfully commercialized continuous tracking for physical metrics like heart rate and blood oxygen, brain health has largely been left behind. Neuratia Labs is addressing this glaring gap with a wearable, EEG-based platform designed to continuously capture neural signals. The system will translate these signals into clear, actionable metrics regarding cognitive states such as attention, fatigue, and stress.
At the center of the startup’s product roadmap is ONYX, a non-invasive, head-worn wearable system. The true differentiator for ONYX, however, is its long-term development toward closed-loop capability.
Currently, industry momentum is heavily shifting toward neuromodulation therapies, with growing clinical adoption of techniques like transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS). However, the vast majority of these current systems operate on an open-loop basis, meaning therapies are delivered without any continuous neural feedback from the patient. By integrating real-time EEG sensing with adaptive, feedback-driven neuromodulation, Neuratia Labs aims to build a next-generation system that can sense, interpret, and instantly adapt interventions in real time.
“Today, we measure almost every aspect of physical health continuously, but the brain remains largely unmeasured outside clinical settings,” said Shaikh, Founder and CEO of Neuratia Labs. “Our goal is to make brain activity measurable in real time, and ultimately usable for improving outcomes in mental health and neuro-rehabilitation”.
The company will initially target two primary domains: mental health and cognitive performance, and neuro-rehabilitation. This dual focus allows for earlier detection in mental health care, while also extending physical and cognitive recovery monitoring well beyond the walls of traditional clinics. Neuratia’s technological approach is heavily rooted in established neuroscience insights which dictate that conditions like depression and cognitive impairment are rarely localized to a single region of the brain; rather, they arise from complex, network-level dysfunction. By pairing real-time EEG sensing with advanced AI signal processing, the startup aims to capture these network dynamics as they actively evolve, rather than reacting long after symptoms physically manifest.
Leveraging Shaikh’s extensive background in applied AI and neuroscience research, Neuratia Labs is currently in the prototype development stage. The startup is already initiating discussions with healthcare providers and research partners to launch pilot studies, validate the hardware in real-world environments, and seamlessly integrate the platform into existing clinical workflows. By translating complex academic research into a deployable, consumer-ready platform, Neuratia Labs is positioning itself at the forefront of the brain-computer interface revolution.
